A 24-week, Randomised, Multi-centre, Double-blind, Parallel-group Trial to Investigate the Safety and the Efficacy of NN2000-Mix30 Compared to NN-X14Mix30 NovoRapid30Mix) in Subjects With Type 2 Diabetes Mellitus on a Twice Daily Regimen
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 17 Jun 2009 Actual patient number (126) added as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.